51
|
Wu R, Zhang Z, Wang B, Chen G, Zhang Y, Deng H, Tang Z, Mao J, Wang L. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles. DRUG DESIGN DEVELOPMENT AND THERAPY 2020; 14:2249-2261. [PMID: 32606595 PMCID: PMC7293388 DOI: 10.2147/dddt.s246574] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/19/2020] [Accepted: 04/15/2020] [Indexed: 12/14/2022]
Abstract
Purpose Lung cancer is the leading cause of cancer mortality worldwide. Drug resistance is the major barrier for the treatment of non-small cell lung cancer (NSCLC). The aim of this research is to develop an aptamer-decorated hybrid nanoparticle for the co-delivery of docetaxel prodrug (DTXp) and cisplatin (DDP) and to treat lung cancer. Materials and Methods Aptamer-conjugated lipid–polymer ligands and redox-sensitive docetaxel prodrug were synthesized. DTXp and DDP were loaded into the lipid–polymer hybrid nanoparticles (LPHNs). The targeted efficiency of aptamer-decorated, DTXp and DDP co-encapsulated LPHNs (APT-DTXp/DDP-LPHNs) was determined by performing a cell uptake assay by flow cytometry-based analysis. In vivo biodistribution and anticancer efficiency of APT-DTXp/DDP-LPHNs were evaluated on NSCLC-bearing mice xenograft. Results APT-DTXp/DDP-LPHNs had a particle size of 213.5 ± 5.3 nm, with a zeta potential of 15.9 ± 1.9 mV. APT-DTXp/DDP-LPHNs exhibited a significantly enhanced cytotoxicity (drug concentration causing 50% inhibition was 0.71 ± 0.09 μg/mL), synergy antitumor effect (combination index was 0.62), and profound tumor inhibition ability (tumor inhibition ratio of 81.4%) compared with the non-aptamer-decorated LPHNs and single drug-loaded LPHNs. Conclusion Since the synergistic effect of the drugs was found in this system, it would have great potential to inhibit lung tumor cells and in vivo tumor growth.
Collapse
Affiliation(s)
- Ruifeng Wu
- Department of Thoracic Surgery, Baoding No.1 Central Hospital, Baoding, Hebei Province, People's Republic of China
| | - Zhiqiang Zhang
- Department of Thoracic Surgery, Baoding No.1 Central Hospital, Baoding, Hebei Province, People's Republic of China
| | - Baohua Wang
- Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People's Republic of China
| | - Ge Chen
- Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of China
| | - Yaozhong Zhang
- Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of China
| | - Haowen Deng
- Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of China
| | - Zilong Tang
- Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of China
| | - Junjie Mao
- Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of China
| | - Lei Wang
- Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei Province, People's Republic of China
| |
Collapse
|
52
|
Saravanakumar K, Sathiyaseelan A, Mariadoss AVA, Jeevithan E, Hu X, Shin S, Wang MH. Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy. Carbohydr Polym 2020; 245:116407. [PMID: 32718591 DOI: 10.1016/j.carbpol.2020.116407] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 04/22/2020] [Accepted: 04/30/2020] [Indexed: 12/15/2022]
Abstract
The present work was developed the pH dependent-aptamer AS1411 (APT) decorated and erlotinib (En) loaded chitosan nanoparticles (CSNPs) for promising non-small-cell lung carcinoma (NSCLC) treatment. The characterization studies revealed that formulated APT-En-CSNPs were spherical in shape with size of 165.95 d. nm and PDI of 0.212. FTIR spectrum recorded molecular chemical interactions with composition of En or En-CSNPs. Cell viability assay, flow cytometry and fluorescent microscopy results revealed that APT-En-CSNPs triggered cancer cell death through pH-sensitive and nucleolin receptor-targeted release of En. The decoration of the APT improved the cellular uptake of En as evidenced by cellular sensing fluorescence and BioTEM assay. The APT-En-CSNPs induced the apoptosis through excessive ROS generation, nucleus damage and Δψm loss in the A549 cells. Hence, the present study revealed that the APT-En-CSNPs improved the therapeutic efficiency of En in NSCLC through the nucleolin targeted drug release.
Collapse
Affiliation(s)
- Kandasamy Saravanakumar
- Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon National University, Chuncheon, 200-701, South Korea
| | - Anbazhagan Sathiyaseelan
- Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon National University, Chuncheon, 200-701, South Korea
| | - Arokia Vijaya Anand Mariadoss
- Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon National University, Chuncheon, 200-701, South Korea
| | - Elango Jeevithan
- Department of Marine Bio-Pharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China
| | - Xiaowen Hu
- Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon National University, Chuncheon, 200-701, South Korea
| | - Sukjin Shin
- Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon National University, Chuncheon, 200-701, South Korea
| | - Myeong-Hyeon Wang
- Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon National University, Chuncheon, 200-701, South Korea.
| |
Collapse
|
53
|
Yalcin TE, Ilbasmis-Tamer S, Takka S. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo. Int J Pharm 2020; 580:119246. [PMID: 32205141 DOI: 10.1016/j.ijpharm.2020.119246] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Revised: 03/18/2020] [Accepted: 03/19/2020] [Indexed: 12/15/2022]
Abstract
The present study demonstrated the application of gemcitabine hydrochloride (GEM) loaded lipid polymer hybrid nanoparticles (LPHNs) for the enhancement the chemotherapeutic response. GEM, which is an anti-tumor drug, is frequently utilized for the treatment of non-small cell lung cancer, breast cancer and pancreatic cancer. GEM loaded LPHNs were formed and examined for pharmacokinetic profile and in vivo anticancer activity. Modified double emulsion solvent evaporation method was employed in the preparation of the LPHNs. Cytotoxicities of the GEM loaded LPHNs formulation were evaluated on MCF-7 and MDA-MB-231 cells by MTT assays. Pharmacokinetics and in vivo anticancer efficacy studies were conducted following intraperitoneal administration in female Sprague-Dawley rats. In vivo pharmacokinetic studies in rats exhibited the advantage of the GEM loaded LPHNs over commercial product Gemko® and the GEM loaded LPHNs had longer circulation time. The half-life of GEM in LPHNs formulation was notable advanced (4.2 folds) comparing to commercial product of GEM (native). These findings indicated that GEM loaded LPHNs can be used for enhancing antitumor efficacy for breast cancer treatment.
Collapse
Affiliation(s)
- Tahir Emre Yalcin
- Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06330 Etiler, Ankara, Turkey
| | - Sibel Ilbasmis-Tamer
- Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06330 Etiler, Ankara, Turkey
| | - Sevgi Takka
- Gazi University, Faculty of Pharmacy, Department of Pharmaceutical Technology, 06330 Etiler, Ankara, Turkey.
| |
Collapse
|
54
|
Wang CX, Ai SL, Wu B, Huang SW, Liu Z. Biotinylated and fluorophore-incorporated polymeric mixed micelles for tumor cell-specific turn-on fluorescence imaging of Al 3. J Mater Chem B 2020; 8:3557-3565. [PMID: 31560346 DOI: 10.1039/c9tb01508f] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Excessive amounts of Al3+ in the human body can cause adverse effects on immune function and induce several neurodegenerative disorders. So far, most of the reported fluorescent probes for Al3+ present some common drawbacks, such as low sensitivity and poor water solubility. In addition, a number of traditional fluorescent probes failed to image Al3+ in tumor cells due to the lack of tumor cell targeting capacity and cell penetrating abilities. To overcome these shortcomings, we constructed tumor-targeting fluorescent mixed nano-micelles (mPEG-Dye-Biotin) with an average particle size of 21 nm from an amphiphilic polymer containing a Schiff-base fluorescent unit (mPEG-Dye) and another amphiphilic polymer containing a tumor cell recognition ligand (DSPE-PEG-Biotin), through the co-self-assembly of both amphiphilic polymers in water using the film rehydration method. The as-prepared nanoprobe showed a highly sensitive and selective turn-on fluorescence response to Al3+ in aqueous solution with a low detection limit. MTT assay revealed the negligible cytotoxicity of the mPEG-Dye-Biotin nanoprobe to both HeLa cells and COS-7 cells, indicating the safety of mPEG-Dye-Biotin for biological applications. More importantly, the biotinylated nanoprobe showed better ability to enter biotin receptor-positive HeLa cells than that of the non-biotinylated micelle mPEG-Dye, which made it more suitable for imaging Al3+ in biotin receptor-positive tumor cells. This work provides a simple and general strategy to design a highly sensitive and tumor cell-specific metal ion nanoprobe, which can not only be applied in Al3+ imaging, but can also be extended to other ions or biomolecules by changing the incorporated fluorescent unit in the amphiphilic polymer.
Collapse
Affiliation(s)
- Cai-Xia Wang
- Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Ministry of Education Key Laboratory for the Synthesis and Application of Organic Functional Molecules and College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, P. R. China.
| | | | | | | | | |
Collapse
|
55
|
Pang J, Xing H, Sun Y, Feng S, Wang S. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab. Biomed Pharmacother 2020; 125:109861. [PMID: 32070872 DOI: 10.1016/j.biopha.2020.109861] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2019] [Revised: 12/10/2019] [Accepted: 12/18/2019] [Indexed: 12/22/2022] Open
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid-polymer hybrid nanoparticles (LPH NPs) to co-deliver erlotinib (ERL) and bevacizumab (BEV) (HA-ERL/BEV-LPH NPs) for targeting and suppressing NSCLC. HA contained pH sensitive nano-materials were synthesized by acylation reaction. HA-ERL/BEV-LPH NPs were prepared using a sonication method. To explore the efficiency of the system, we evaluated the physicochemical parameters and performed a release study, a cellular uptake assay, a cytotoxicity evaluation, and several in vivo anti-tumor studies in comparison with free drugs and single drug systems. All LPH NPs samples have particle sizes of about 100-120 nm, polydispersity index values range from 0.12 to 0.15, and negative zeta potentials. HA-ERL/BEV-LPH NPs contained pH sensitive adipic acid dihydrazide (ADH) showed fast drug release at pH 5.5 than pH 7.4. After 21 days, the tumor volume of the HA-ERL/BEV-LPH NPs group (229.2 ± 13.1 mm3) was significantly smaller than 0.9 % NaCl control group (1126.3 ± 39.4 mm3), with a tumor inhibition rate of 79.7 ± 3.2 %. The maximum plasma ERL concentrations, half life period, and area under the curve of HA-ERL/BEV-LPH NPs were 21.6 μg/mL, 7.57 h, and 290.3 mg/L·h). With the highest tumor tissue accumulation concentration (25.3 μg/mL) and low system toxicity, HA-ERL/BEV-LPH NPs. HA-ERL/BEV-LPH NPs could be used as a promising system for the combination therapy of NSCLC.
Collapse
Affiliation(s)
- Juntao Pang
- Department of Critical Care Medicine, Weifang People's Hospital, Weifang, 261000, Shandong Province, China
| | - Huaixin Xing
- Department of Anesthesiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong Province, China
| | - Yingui Sun
- Department of Anesthesiology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, Shandong Province, China
| | - Shuo Feng
- Department of Gynaecology, Affiliated Hospital of Weifang Medical University, Weifang, 261031, Shandong Province, China
| | - Suzhen Wang
- Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, No. 440 Jiyan Road, Huaiyin District, Jinan, 250117, Shandong Province, China.
| |
Collapse
|
56
|
Khan MM, Madni A, Torchilin V, Filipczak N, Pan J, Tahir N, Shah H. Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin. Drug Deliv 2020; 26:765-772. [PMID: 31357896 PMCID: PMC6711028 DOI: 10.1080/10717544.2019.1642420] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratios were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181–245 nm and a zeta potential range of 20–30 mV. The stability of the formulation was demonstrated by thermal studies. Cytotoxicity and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays using the A2780 ovarian carcinoma cell line. The pharmacokinetics study in rabbits supported a controlled delivery of cisplatin with enhanced mean residence time and half-life. These studies suggest that cisplatin loaded LPHNP have promise as a platform for controlled delivery of cisplatin in cancer therapy.
Collapse
Affiliation(s)
- Muhammad Muzamil Khan
- a Center of Pharmaceutical Biotechnology and Nanomedicines, Northeastern University , Boston , MA , USA.,b Department of Pharmacy, The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Asadullah Madni
- b Department of Pharmacy, The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Vladimir Torchilin
- a Center of Pharmaceutical Biotechnology and Nanomedicines, Northeastern University , Boston , MA , USA
| | - Nina Filipczak
- a Center of Pharmaceutical Biotechnology and Nanomedicines, Northeastern University , Boston , MA , USA.,c Department of Biotechnology, Laboratory of Lipids and Liposomes, University of Wroclaw , Wroclaw , Poland
| | - Jiayi Pan
- a Center of Pharmaceutical Biotechnology and Nanomedicines, Northeastern University , Boston , MA , USA
| | - Nayab Tahir
- d College of Pharmacy, University of Sargodha , Sargodha , Pakistan
| | - Hassan Shah
- b Department of Pharmacy, The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| |
Collapse
|
57
|
Truong DH, Le VKH, Pham TT, Dao AH, Pham TPD, Tran TH. Delivery of erlotinib for enhanced cancer treatment: An update review on particulate systems. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2019.101348] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
58
|
Mycophenolate co-administration with quercetin via lipid-polymer hybrid nanoparticles for enhanced breast cancer management. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2020; 24:102147. [DOI: 10.1016/j.nano.2019.102147] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 11/27/2019] [Accepted: 12/15/2019] [Indexed: 01/31/2023]
|
59
|
Hamdi M, Abdel-Bar HM, Elmowafy E, Al-Jamal KT, Awad GAS. An integrated vitamin E-coated polymer hybrid nanoplatform: A lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect. PLoS One 2020; 15:e0227231. [PMID: 31923260 PMCID: PMC6953793 DOI: 10.1371/journal.pone.0227231] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 12/13/2019] [Indexed: 01/19/2023] Open
Abstract
A platform capable of specifically delivering an antiviral drug to the liver infected with hepatitis B is a major concern in hepatology. Vaccination has had a major effect on decreasing the emerging numbers of new cases of infection. However, the total elimination of the hepatitis B virus from the body requires prolonged therapy. In this work, we aimed to target the liver macrophages with lipid polymer hybrid nanoparticles (LPH), combining the merit of polymeric nanoparticles and lipid vesicles. The hydrophilic antiviral drug, entecavir (E), loaded LPH nanoparticles were optimized and physicochemically characterized. A modulated lipidic corona, as well as, an additional coat with vitamin E were used to extend the drug release enhance the macrophage uptake. The selected vitamin E coated LPH nanoparticles enriched with lecithin-glyceryl monostearate lipid shell exhibited high entrapment for E (80.47%), a size ≤ 200 nm for liver passive targeting, extended release over one week, proven serum stability, retained stability after refrigeration storage for 6 months. Upon macrophage uptake in vitro assessment, the presented formulation displayed promising traits, enhancing the cellular retention in J774 macrophages cells. In vivo and antiviral activity futuristic studies would help in the potential application of the ELPH in hepatitis B control.
Collapse
Affiliation(s)
- Mohamed Hamdi
- Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt
| | - Hend Mohamed Abdel-Bar
- Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Sadat City, Egypt
| | - Enas Elmowafy
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Sadat City, Egypt
| | - Khuloud T. Al-Jamal
- Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King’s College London, England, United Kingdom
| | - Gehanne A. S. Awad
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Sadat City, Egypt
| |
Collapse
|
60
|
Zhou X, Shi K, Hao Y, Yang C, Zha R, Yi C, Qian Z. Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. Asian J Pharm Sci 2020; 15:26-41. [PMID: 32175016 PMCID: PMC7066044 DOI: 10.1016/j.ajps.2019.06.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 05/30/2019] [Accepted: 06/14/2019] [Indexed: 02/05/2023] Open
Abstract
Oral tyrosine kinase inhibitors (TKIs) against epidermal growth factor receptor (EGFR) family have been introduced into the clinic to treat human malignancies for decades. Despite superior properties of EGFR-TKIs as small molecule targeted drugs, their applications are still restricted due to their low solubility, capricious oral bioavailability, large requirement of daily dose, high binding tendency to plasma albumin and initial/acquired drug resistance. Nanotechnology is a promising tool to improve efficacy of these drugs. Through non-oral routes. Various nanotechnology-based delivery approaches have been developed for providing efficient delivery of EGFR-TKIs with a better pharmacokinetic profile and tissue-targeting ability. This review aims to indicate the advantage of nanocarriers for EGFR-TKIs delivery.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Zhiyong Qian
- Department of Medical Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| |
Collapse
|
61
|
Inhalable hybrid nanocarriers for respiratory disorders. TARGETING CHRONIC INFLAMMATORY LUNG DISEASES USING ADVANCED DRUG DELIVERY SYSTEMS 2020. [PMCID: PMC7499343 DOI: 10.1016/b978-0-12-820658-4.00013-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Rapid advancements in the field of drug delivery lead to increased use of inhalable formulations as they are cost effective, noninvasive, and targeted and have less systemic side effects and above all better patient compliance. Development of inhalable hybrid systems has offered manifold advantages to this area of drug delivery. Inclusion of polymer and lipid, inorganic and organic substances, and metallic nanoparticles all of them aim to achieve codelivery of drugs which are incompatible in single phase systems. The recent progress in nanotechnology has gained momentum toward delivery of siRNA and miRNA and vaccines to the targeted site. The present work is an attempt to compile all the hybrid and inhalable systems to give readers an overview toward this delivery system as much more work is needed in this field to achieve better resolution of inflammatory disorders.
Collapse
|
62
|
Harwansh RK, Deshmukh R, Barkat MA, Rahman MA. Bioinspired Polymeric-based Core-shell Smart Nano-systems. Pharm Nanotechnol 2019; 7:181-205. [PMID: 31486750 DOI: 10.2174/2211738507666190429104550] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 12/03/2018] [Accepted: 04/10/2019] [Indexed: 12/20/2022]
Abstract
Smart nanosystems (SNs) have the potential to revolutionize drug delivery. Conventional drug delivery systems have poor drug-loading, early burst release, limited therapeutic effects, etc. Thus, to overcome these problems, researchers have taken advantage of the host-guest interactions as bioinspired nanosystems which can deliver nanocarriers more efficiently with the maximum drug loading capacity and improved therapeutic efficacy as well as bioavailability. SNs employ nanomaterials to form cage molecules by entrapping new nanocarriers called smart nanosystems in their cargo and design. The activities of SNs are based on responsive materials that interact with the stimuli either by changing their properties or conformational structures. The aptitude of living systems to respond to stimuli and process information has encouraged researchers to build up integrated nanosystems exhibiting similar function and therapeutic response. Various smart materials, including polymers, have been exhaustively employed in fabricating different stimuli-responsive nanosystems which can deliver bioactive molecules to a specific site for a certain period with minimal side effects. SNs have been widely explored to deliver diverse kinds of therapeutic agents ranging from bioactive compounds, genes, and biopharmaceuticals like proteins and peptides, to diagnostic imaging agents for biomedical applications. Nanotechnology-based different nanosystems are promising for health care issues. The advancement of SNs with physical science and engineering technology in synthesizing nanostructures and their physicochemical characterization should be exploited in medicine and healthcare for reducing mortality rate, morbidity, disease prevalence and general societal burden.
Collapse
Affiliation(s)
- Ranjit K Harwansh
- Institute of Pharmaceutical Research, GLA University, Mathura -281406, India
| | - Rohitas Deshmukh
- Institute of Pharmaceutical Research, GLA University, Mathura -281406, India
| | - Md Abul Barkat
- Department of Pharmaceutics, School of Medical and Allied Sciences, K.R. Mangalam University, Sohna, Gurgaon, India
| | | |
Collapse
|
63
|
Biomimetic nanostructures/cues as drug delivery systems: a review. MATERIALS TODAY CHEMISTRY 2019. [DOI: 10.1016/j.mtchem.2019.06.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
64
|
Kamel NM, Helmy MW, Samaha MW, Ragab D, Elzoghby AO. Multicompartmental lipid–protein nanohybrids for combined tretinoin/herbal lung cancer therapy. Nanomedicine (Lond) 2019; 14:2461-2479. [DOI: 10.2217/nnm-2019-0090] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Aim: Multicompartmental lipid–protein nanohybrids (MLPNs) were developed for combined delivery of the anticancer drugs tretinoin (TRE) and genistein (GEN) as synergistic therapy of lung cancer. Materials & methods: The GEN-loaded lipid core was first prepared and then coated with TRE-loaded zein shell via nanoprecipitation. Results: TRE/GEN-MLPNs demonstrated a size of 154.5 nm. In situ ion pair formation between anionic TRE and the cationic stearyl amine improved the drug encapsulation with enhanced stability of MLPNs. TRE/GEN-coloaded MLPNs were more cytotoxic against A549 cancer cells compared with combined free GEN/TRE. In vivo, lung cancer bearing mice treated with TRE/GEN-MLPNs displayed higher apoptotic caspase activation compared with mice-treated free combined GEN/TRE. Conclusion: TRE/GEN-MLPNs might serve as a promising parenteral nanovehicles for lung cancer therapy.
Collapse
Affiliation(s)
- Nayra M Kamel
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
| | - Maged W Helmy
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhur University, Damanhur, 22516, Egypt
| | - Magda W Samaha
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
| | - Doaa Ragab
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
| | - Ahmed O Elzoghby
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, 21521, Egypt
- Department of Medicine, Division of Engineering in Medicine, Brigham & Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
- Harvard-MIT Division of Health Sciences & Technology (HST), Cambridge, MA 02139, USA
| |
Collapse
|
65
|
Zhan C, Huang Y, Lin G, Huang S, Zeng F, Wu S. A Gold Nanocage/Cluster Hybrid Structure for Whole-Body Multispectral Optoacoustic Tomography Imaging, EGFR Inhibitor Delivery, and Photothermal Therapy. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2019; 15:e1900309. [PMID: 31245925 DOI: 10.1002/smll.201900309] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Revised: 04/25/2019] [Indexed: 06/09/2023]
Abstract
Gold nanocages (AuNCs) and gold nanoclusters (AuClusters) are two classes of advantageous nanostructures with special optical properties, and many other attractive properties. Integrating them into one nanosystem may achieve greater and smarter performance. Herein, a hybrid gold nanostructure for fluorescent and optoacoustic tomography imaging, controlled release of drugs, and photothermal therapy (PTT) is demonstrated. For this nanodrug (EA-AB), an epidermal growth factor receptor (EGFR) inhibitor erlotinib (EB) is loaded into AuNCs, which are then capped and functionalized by biocompatible AuCluster@BSA (BSA = bovine serum albumin) conjugates via electrostatic interaction. Upon cell internalization, the lysosomal proteases and low pH cause the release of EB from EA-AB, and also induce fluorescence restoration of the AuCluster for imaging. Irradiation with near-infrared light further promotes the drug release and affords a PTT effect as well. The AuNC-based nanodrug is optoacoustically active, and its biodistribution and metabolic process have been successfully monitored by whole-body and 3D multispectral optoacoustic tomography imaging. Owing to the combined actions of PTT and EGFR pathway blockage, EA-AB exhibits marked tumor inhibition efficacy in vivo.
Collapse
Affiliation(s)
- Chenyue Zhan
- State Key Laboratory of Luminescent Materials and Devices, College of Materials Science and Engineering, South China University of Technology, Wushan Road 381, Guangzhou, 510640, China
| | - Yong Huang
- State Key Laboratory of Luminescent Materials and Devices, College of Materials Science and Engineering, South China University of Technology, Wushan Road 381, Guangzhou, 510640, China
| | - Guifang Lin
- State Key Laboratory of Luminescent Materials and Devices, College of Materials Science and Engineering, South China University of Technology, Wushan Road 381, Guangzhou, 510640, China
| | - Shuailing Huang
- State Key Laboratory of Luminescent Materials and Devices, College of Materials Science and Engineering, South China University of Technology, Wushan Road 381, Guangzhou, 510640, China
| | - Fang Zeng
- State Key Laboratory of Luminescent Materials and Devices, College of Materials Science and Engineering, South China University of Technology, Wushan Road 381, Guangzhou, 510640, China
| | - Shuizhu Wu
- State Key Laboratory of Luminescent Materials and Devices, College of Materials Science and Engineering, South China University of Technology, Wushan Road 381, Guangzhou, 510640, China
| |
Collapse
|
66
|
Bera H, Ang SR, Chiong SW, Chan CH, Abbasi YF, Law LP, Chatterjee B, Venugopal V. Core-shell structured pullulan based nanocomposites as erlotinib delivery shuttles. INT J POLYM MATER PO 2019. [DOI: 10.1080/00914037.2019.1626389] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- Hriday Bera
- Faculty of Pharmacy, AIMST University, Bedong, Malaysia
| | - Sher Reen Ang
- Faculty of Pharmacy, AIMST University, Bedong, Malaysia
| | | | | | | | - Lee Ping Law
- Faculty of Pharmacy, AIMST University, Bedong, Malaysia
| | - Bappadity Chatterjee
- Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuala Lumpur, Malaysia
| | | |
Collapse
|
67
|
Narmani A, Rezvani M, Farhood B, Darkhor P, Mohammadnejad J, Amini B, Refahi S, Abdi Goushbolagh N. Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems. Drug Dev Res 2019; 80:404-424. [PMID: 31140629 DOI: 10.1002/ddr.21545] [Citation(s) in RCA: 103] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 03/02/2019] [Accepted: 05/07/2019] [Indexed: 12/15/2022]
Abstract
Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitations of conventional drug delivery systems (DDSs) including nonspecific biodistribution and targeting, poor water solubility, weak bioavailability and biodegradability, low pharmacokinetic properties, and so forth. The enhanced permeability and retention effect escape from P-glycoprotein trap in cancer cells as a passive targeting mechanism, and active targeting strategies are also other most important advantages of NPs in cancer diagnosis and therapy. Folic acid (FA) is one of the biologic molecules which has been targeted overexpressed-folic acid receptor (FR) on the surface of cancer cells. Therefore, conjugation of FA to NPs most easily enhances the FR-mediated targeting delivery of therapeutic agents. Here, the recent works in FA which have been decorated NPs-based DDSs are discussed and cancer therapy potency of these NPs in clinical trials are presented.
Collapse
Affiliation(s)
- Asghar Narmani
- Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran
| | - Melina Rezvani
- Department of Biology, Faculty of Sciences, Payame Noor University, Tehran, Iran
| | - Bagher Farhood
- Department of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran
| | - Parvaneh Darkhor
- Department of Medical Physics, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Javad Mohammadnejad
- Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran
| | - Bahram Amini
- Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Soheila Refahi
- Department of Medical Physics, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Nouraddin Abdi Goushbolagh
- Department of Medical Physics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| |
Collapse
|
68
|
Kamel NM, Helmy MW, Abdelfattah EZ, Khattab SN, Ragab D, Samaha MW, Fang JY, Elzoghby AO. Inhalable Dual-Targeted Hybrid Lipid Nanocore–Protein Shell Composites for Combined Delivery of Genistein and All-Trans Retinoic Acid to Lung Cancer Cells. ACS Biomater Sci Eng 2019; 6:71-87. [DOI: 10.1021/acsbiomaterials.8b01374] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Nayra M. Kamel
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Maged W. Helmy
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
| | | | - Sherine N. Khattab
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Chemistry, Faculty of Science, Alexandria University, Alexandria 21321, Egypt
| | - Doaa Ragab
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Magda W. Samaha
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Jia-You Fang
- Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Taoyuan 333, Taiwan
- Research Center for Industry of Human Ecology and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan 333, Taiwan
- Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan 333, Taiwan
| | - Ahmed O. Elzoghby
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United States
- Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
69
|
Espinoza SM, Patil HI, San Martin Martinez E, Casañas Pimentel R, Ige PP. Poly-ε-caprolactone (PCL), a promising polymer for pharmaceutical and biomedical applications: Focus on nanomedicine in cancer. INT J POLYM MATER PO 2019. [DOI: 10.1080/00914037.2018.1539990] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Sergio Miguel Espinoza
- Instituto Politécnico Nacional, Centro de Investigación en Ciencia Aplicada y Tecnología Avanzada, Legaria 694, Col. Irrigación, 11500 Ciudad de México
| | - Harshal Indrabhan Patil
- Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra 425405, India
| | - Eduardo San Martin Martinez
- Instituto Politécnico Nacional, Centro de Investigación en Ciencia Aplicada y Tecnología Avanzada, Legaria 694, Col. Irrigación, 11500 Ciudad de México
| | - Rocio Casañas Pimentel
- CONACYT-Instituto Politécnico Nacional, Centro de Investigación en Ciencia Aplicada y Tecnología Avanzada, Legaria 694, Col. Irrigación, 11500 Ciudad de México
| | - Pradum Pundlikrao Ige
- Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, Maharashtra 425405, India
| |
Collapse
|
70
|
Mottaghitalab F, Farokhi M, Fatahi Y, Atyabi F, Dinarvand R. New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment. J Control Release 2019; 295:250-267. [DOI: 10.1016/j.jconrel.2019.01.009] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2018] [Revised: 01/07/2019] [Accepted: 01/09/2019] [Indexed: 12/22/2022]
|
71
|
Kurbanoglu S, Bakirhan NK, Gumustas M, Ozkan SA. Modern Assay Techniques for Cancer Drugs: Electroanalytical and Liquid Chromatography Methods. Crit Rev Anal Chem 2019; 49:306-323. [PMID: 30595027 DOI: 10.1080/10408347.2018.1527206] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
In the past decades, patients who have chemotherapy treatment have considerably increased number. At this point, the development of rapid precise, and reliable methods are very important to analyze cancer drugs from their dosage forms, animals or human biological samples. Among all the analytical methods, electrochemical methods hold an important position with their unique properties such as specificity in the biological recognition process, fast response, and their reliability and do not need a pretreatment process. Chromatographic methods are also used in a wide range of analytical applications for the analyses of anticancer drugs. The power of chromatography comes from its ability to separate a mixture of analytes and determination of their concentrations. Chromatographic techniques can mainly be divided into gas, liquid, and supercritical fluid chromatography. In the frame of this information, this review is aimed to provide basic principles of electroanalytical and high-performance liquid chromatography methods for the analysis of cancer drugs. In addition, some selected applications for electrochemistry-related techniques and high-performance liquid chromatography, for the determination of anti-cancer pharmaceuticals published in the last five years are also discussed.
Collapse
Affiliation(s)
- Sevinc Kurbanoglu
- a Faculty of Pharmacy, Department of Analytical Chemistry , Ankara University , Ankara , Turkey
| | - Nurgul K Bakirhan
- b Faculty of Science and Art, Department of Chemistry , Hitit University , Çorum , Turkey
| | - Mehmet Gumustas
- c Department of Forensic Toxicology , Ankara University Institute of Forensic Sciences , Ankara , Turkey
| | - Sibel A Ozkan
- a Faculty of Pharmacy, Department of Analytical Chemistry , Ankara University , Ankara , Turkey
| |
Collapse
|
72
|
Chen D, Zhang F, Wang J, He H, Duan S, Zhu R, Chen C, Yin L, Chen Y. Biodegradable Nanoparticles Mediated Co-delivery of Erlotinib (ELTN) and Fedratinib (FDTN) Toward the Treatment of ELTN-Resistant Non-small Cell Lung Cancer (NSCLC) via Suppression of the JAK2/STAT3 Signaling Pathway. Front Pharmacol 2018; 9:1214. [PMID: 30483119 PMCID: PMC6242943 DOI: 10.3389/fphar.2018.01214] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2018] [Accepted: 10/05/2018] [Indexed: 12/19/2022] Open
Abstract
Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side effects, and drug resistance, which poses critical challenges in the clinical setting. Acquired resistance of ELTN results in extremely poor prognoses of non-small cell lung cancer (NSCLC) patients, wherein activation of the JAK2/STAT3 signaling pathway has been proven to induce acquired ELTN resistance. Methods: In this study, we developed a nanoparticle (NP) delivery system based on Food and Drug Administration (FDA)-approved poly(ethylene glycol) (PEG)-poly(lactic acid) (PLA) for the co-delivery of ELTN and fedratinib (FDTN, a small-molecular, highly selective JAK2 inhibitor). Both ELTN and FDTN could be encapsulated into the PEG-PLA NPs via optimization of the encapsulation method. The effect of NPs on NSCLC cells was evaluated by MTT assay. Western blotting was performed to study the molecular mechanisms of NPs inhibiting the downstream pathways of EGFR in vitro. The histological analysis and protein expression in vivo were assessed by hematoxylin/eosin (H&E) staining and immunohistochemistry, respectively. Results: The drug cargoes exhibited great stability, and could be released more efficiently in the acidic tumorous condition. Mechanistic study showed that FDTN notably down-regulated the expression levels of proteins in the JAK2/STAT3 signaling pathway, including p-EGFR, p-JAK2, p-STAT3 and Survivin, therefore reversing the ELTN resistance. As a result, synergistic anti-cancer effect was achieved by PEG-PLA NPs encapsulating both ELTN and FDTN in ELTN-resistant NSCLC tumors both in vitro and in vivo, and lower systemic side effect was noted for the co-delivery NPs compared to free drugs. Conclusion: This study provides a promising approach to overcome the ELTN resistance in the treatment of NSCLC, and the use of FDA-approved materials with clinically applied/investigated chemical drugs may facilitate the translation of the current delivery system.
Collapse
Affiliation(s)
- Donglai Chen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
| | - Fuquan Zhang
- Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Jinhui Wang
- Institute of Functional Nano and Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, China
| | - Hua He
- Institute of Functional Nano and Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, China
| | - Shanzhou Duan
- Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Rongying Zhu
- Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
| | - Chang Chen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
| | - Lichen Yin
- Institute of Functional Nano and Soft Materials, Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, China
| | - Yongbing Chen
- Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
| |
Collapse
|
73
|
Vaidya B, Parvathaneni V, Kulkarni NS, Shukla SK, Damon JK, Sarode A, Kanabar D, Garcia JV, Mitragotri S, Muth A, Gupta V. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int J Biol Macromol 2018; 122:338-347. [PMID: 30401652 DOI: 10.1016/j.ijbiomac.2018.10.181] [Citation(s) in RCA: 79] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Revised: 10/24/2018] [Accepted: 10/25/2018] [Indexed: 01/10/2023]
Abstract
This study was aimed at developing a nanoparticle strategy to overcome acquired resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on biodegradable PLGA nanoparticles, erlotinib-cyclodextrin (Erlo-CD) complex was prepared using β-cyclodextrin sulfobutyl ether, which was in turn loaded in the core of PLGA nanoparticles using multiple emulsion solvent evaporation. Nanoparticles were characterized for size distribution, entrapment and loading efficiency, in-vitro release, and therapeutic efficacy against different lung cancer cells. Effect of formulation on cell cycle, apoptosis, and other markers was evaluated using flow cytometry and western blotting studies. The efficacy of optimized nanoformulation was evaluated using a clinically relevant in-vitro 3D-spheroid model. Results showed that Erlo-CD loaded nanoparticles (210 ± 8 nm in size) demonstrated 3-fold higher entrapment (61.5 ± 3.2% vs 21.9 ± 3.7% of plain erlotinib loaded nanoparticles) with ~5% loading efficiency and sustained release characteristics. Developed nanoparticles demonstrated significantly improved therapeutic efficacy against NSCLC cells in terms of low IC50 values and suppressed colony forming ability of cancer cells, increased apoptosis, and autophagy inhibition. Interestingly, 3D spheroid study demonstrated better anticancer activity of Erlo-CD nanoparticles compared to plain erlotinib. Present study has shown a premise to improve therapeutic efficacy against erlotinib-resistant lung cancer using modified nanoErlo formulations.
Collapse
Affiliation(s)
- Bhuvaneshwar Vaidya
- School of Pharmacy, Keck Graduate Institute, Claremont, CA 91711, United States of America
| | - Vineela Parvathaneni
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States of America
| | - Nishant S Kulkarni
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States of America
| | - Snehal K Shukla
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States of America
| | - Jenna K Damon
- Department of Biology, University of La Verne, La Verne, CA 91750, United States of America
| | - Apoorva Sarode
- John A Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, United States of America
| | - Dipti Kanabar
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States of America
| | - Jerome V Garcia
- Department of Biology, University of La Verne, La Verne, CA 91750, United States of America
| | - Samir Mitragotri
- John A Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, United States of America
| | - Aaron Muth
- College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States of America
| | - Vivek Gupta
- School of Pharmacy, Keck Graduate Institute, Claremont, CA 91711, United States of America; College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, United States of America.
| |
Collapse
|
74
|
Liu J, Cheng H, Han L, Qiang Z, Zhang X, Gao W, Zhao K, Song Y. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. DRUG DESIGN DEVELOPMENT AND THERAPY 2018; 12:3199-3209. [PMID: 30288024 PMCID: PMC6161729 DOI: 10.2147/dddt.s172199] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Purpose Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric nanoparticles and liposomes into a single delivery platform. In this study, we engineered LPNs as the co-delivery system of paclitaxel (PTX) and triptolide (TL) to achieve synergistic therapeutic effect and reduced drug resistance. Materials and methods In this study, PTX- and TL-coloaded LPNs (P/T-LPNs) were fabricated by nanoprecipitation method using lipid and polymeric materials. The P/T-LPNs combination effects on human lung cancer cells were studied. Therapeutic potentials of P/T-LPNs were further determined using lung cancer cells-bearing mice model. Results The average particle sizes of LPNs were around 160 nm, with narrow size distribution below 0.2. The zeta potential value of LPNs was about −30 mV. The encapsulating efficiency (EE) of PTX and TL loaded in LPNs was over 85%. The cytotoxicity of dual drug loaded LPNs was higher than single drug loaded LPNs. The combination therapy showed synergistic when PTX:TL weight ratio was 5:3, indicating the synergy effects of the LPNs. In vivo tumor growth curve of the experimental group was more gentle opposed to the control group, and tumor volumes of P/T-LPNs and control group were 392 and 1,737 mm3, respectively. The inhibition rate on day 20 was 77.4% in the P/T-LPNs group, which is higher than the free drugs solution. Conclusion The in vivo and in vitro results proved the synergetic effect of the two drugs coloaded in LPNs on the lung cancer xenografts, with the least systemic toxic side effect.
Collapse
Affiliation(s)
- Jia Liu
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| | - Hao Cheng
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| | - Le Han
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| | - Zhun Qiang
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| | - Xinwei Zhang
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| | - Wei Gao
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| | - Kun Zhao
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| | - Yangrong Song
- Department of Thoracic Surgery, Tumor Hospital of Shaanxi Province, Xi'an, Shaanxi, People's Republic of China,
| |
Collapse
|
75
|
Zhang B, Zheng M, Cai L, Fan X. Synthesis and Characterization of Placental Chondroitin Sulfate A (plCSA)-Targeting Lipid-Polymer Nanoparticles. J Vis Exp 2018:58209. [PMID: 30295666 PMCID: PMC6235189 DOI: 10.3791/58209] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
An effective cancer therapeutic method reduces and eliminates tumors with minimal systemic toxicity. Actively targeting nanoparticles offer a promising approach to cancer therapy. The glycosaminoglycan placental chondroitin sulfate A (plCSA) is expressed on a wide range of cancer cells and placental trophoblasts, and malarial protein VAR2CSA can specifically bind to plCSA. A reported placental chondroitin sulfate A binding peptide (plCSA-BP), derived from malarial protein VAR2CSA, can also specifically bind to plCSA on cancer cells and placental trophoblasts. Hence, plCSA-BP-conjugated nanoparticles could be used as a tool for targeted drug delivery to human cancers and placental trophoblasts. In this protocol, we describe a method to synthesize plCSA-BP-conjugated lipid-polymer nanoparticles loaded with doxorubicin (plCSA-DNPs); the method consists of a single sonication step and bioconjugate techniques. In addition, several methods for characterizing plCSA-DNPs, including determining their physicochemical properties and cellular uptake by placental choriocarcinoma (JEG3) cells, are described.
Collapse
Affiliation(s)
- Baozhen Zhang
- Laboratory for Reproductive Health, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS)
| | - Mingbin Zheng
- Guangdong Key Laboratory of Nanomedicine, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS); Department of Chemistry, Guangdong Medical University
| | - Lintao Cai
- Guangdong Key Laboratory of Nanomedicine, CAS Key Lab for Health Informatics, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS);
| | - Xiujun Fan
- Laboratory for Reproductive Health, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS);
| |
Collapse
|
76
|
Novel core-shell dextran hybrid nanosystem for anti-viral drug delivery. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2018; 93:864-872. [PMID: 30274122 DOI: 10.1016/j.msec.2018.08.015] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2017] [Revised: 07/07/2018] [Accepted: 08/05/2018] [Indexed: 11/20/2022]
Abstract
Zidovudine (AZT) is an antiviral drug extensively used for combating the global pandemic- HIV/AIDS. However, its uses are overshadowed by its short half -life, poor aqueous solubility and inability to cross physiological barriers. This study highlights a nanosystem consisting of dextran and stearic acid for AZT delivery. This hybrid nanoparticle was prepared by double emulsion solvent evaporation method. The morphological analysis of the prepared nanoparticles was carried out by transmission electron microscopy (TEM) and structural analysis through FTIR spectroscopy. Haemolysis, blood cell aggregation and cytotoxicity evaluations were also performed. These biological evaluations indicated that the nanoparticles were compatible and fluorescence microscopy studies demonstrated increased cellular internalization of drug loaded hybrid nanoparticles when compared with free drug molecules. The experimental outcomes indicate that the prepared nanoparticles are highly biocompatible haemocompatible and effective in getting internalized into cells of neural origin. These results highlight the feasibility and efficacy of the hybrid nanoparticles for effective delivery of zidovudine.
Collapse
|
77
|
Guo F, Wu J, Wu W, Huang D, Yan Q, Yang Q, Gao Y, Yang G. PEGylated self-assembled enzyme-responsive nanoparticles for effective targeted therapy against lung tumors. J Nanobiotechnology 2018; 16:57. [PMID: 30012166 PMCID: PMC6048871 DOI: 10.1186/s12951-018-0384-8] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Accepted: 07/06/2018] [Indexed: 01/17/2023] Open
Abstract
Background Matrix-metalloproteinases, which are overexpressed in many types of cancer, can be applied to improve the bioavailability of chemotherapeutic drugs and guide therapeutic targeting. Thus, we aimed to develop enzyme-responsive nanoparticles based on a functionalized copolymer (mPEG-Peptide-PCL), which was sensitive to matrix metalloproteinase, as smart drug vesicles for enhanced biological specificity and reduced side effects. Results The rate of in vitro curcumin (Cur) release from Cur-P-NPs was not markedly accelerated in weakly acidic tumor microenvironment, indicating a stable intracellular concentration and a consistent therapeutic effect. Meanwhile, P-NPs and Cur-P-NPs displayed prominent biocompatibility, biostability, and inhibition efficiency in tumor cells. In addition, Cur-P-NPs showed higher fluorescence intensity than Cur-NPs in tumor cells, implying enhanced cell permeability and targeting ability. Moreover, the internalization and intracellular transport of Cur-P-NPs were mainly via macropinocytosis. Studies of pharmacodynamics and cellular uptake in vitro and biodistribution in vivo demonstrated that Cur-P-NPs had stronger target efficiency and therapeutic effect than Cur-DMSO and Cur-NPs in tumor tissue. Conclusion Results indicate that Cur-P-NPs can be employed for active targeted drug delivery in cancer treatment and other biomedical applications. Electronic supplementary material The online version of this article (10.1186/s12951-018-0384-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Fangyuan Guo
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China
| | - Jiangqing Wu
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China
| | - Wenchao Wu
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China
| | - Dongxue Huang
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China
| | - Qinying Yan
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China
| | - Qingliang Yang
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China
| | - Ying Gao
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China
| | - Gensheng Yang
- College of Pharmaceutical Science, Zhejiang University of Technology, #18 Chaowang Road, Hangzhou, 310032, People's Republic of China.
| |
Collapse
|
78
|
Dudhipala N, Puchchakayala G. Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. Drug Dev Ind Pharm 2018; 44:1572-1582. [DOI: 10.1080/03639045.2018.1445264] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
| | - Goverdhan Puchchakayala
- Department of Pharmacology, Synapse Life Sciences, Vaagdevi College of Pharmacy, Hanmakonda, Warangal, India
| |
Collapse
|
79
|
García-Guzmán P, Medina-Torres L, Calderas F, Bernad-Bernad MJ, Gracia-Mora J, Mena B, Manero O. Characterization of hybrid microparticles/Montmorillonite composite with raspberry-like morphology for Atorvastatin controlled release. Colloids Surf B Biointerfaces 2018; 167:397-406. [DOI: 10.1016/j.colsurfb.2018.04.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Revised: 03/22/2018] [Accepted: 04/04/2018] [Indexed: 11/30/2022]
|
80
|
Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design. Int J Pharm 2018; 548:255-262. [PMID: 29969712 DOI: 10.1016/j.ijpharm.2018.06.063] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 06/28/2018] [Accepted: 06/28/2018] [Indexed: 12/31/2022]
Abstract
Lipid polymer hybrid nanoparticles (LPHNs) combine the characteristics and beneficial properties of both polymeric nanoparticles and liposomes. The objective of this study was to design and optimize gemcitabine hydrochloride loaded LPHNs based on the central composite design approach. PLGA 50:50/PLGA 65:35 mass ratio (w/w), soya phosphatidylcholine (SPC)/polymer mass ratio (%, w/w) and amount of DSPE-PEG were chosen as the investigated independent variables. The LPHNs were prepared with modified double emulsion solvent evaporation method and characterized by testing their particle size, encapsulation efficiency, and cumulative release. The composition of optimal formulation was determined as 1,5 (w/w) PLGA 50:50/PLGA 65:35 mass ratio, 30% (w/w) SPC/polymer mass ratio and 15 mg DSPE-PEG. The results showed that the optimal formulation gemcitabine hydrochloride loaded LPHNs had encapsulation efficiency of 45,2%, particle size of 237 nm and cumulative release of 62,3% at the end of 24 h. The morphology of LPHNs was found to be spherical by transmission electron microscopy (TEM) observation. Stability studies showed that LPHNs were physically stable until 12 months at 4 °C and 9 months at 25 °C/60% RH. The results suggest that the LPHNs can be an effective drug delivery system for hydrophilic active pharmaceutical ingredient.
Collapse
|
81
|
Nimmano N, Somavarapu S, Taylor KM. Aerosol characterisation of nebulised liposomes co-loaded with erlotinib and genistein using an abbreviated cascade impactor method. Int J Pharm 2018; 542:8-17. [DOI: 10.1016/j.ijpharm.2018.02.035] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Revised: 02/08/2018] [Accepted: 02/18/2018] [Indexed: 11/29/2022]
|
82
|
Tan S, Wang G. Lung cancer targeted therapy: Folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed Pharmacother 2018; 102:55-63. [PMID: 29549729 DOI: 10.1016/j.biopha.2018.03.046] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Revised: 03/09/2018] [Accepted: 03/09/2018] [Indexed: 10/17/2022] Open
Abstract
To achieve lung cancer targeted therapy, folic acid (FA) and transferrin (Tf) modified cisplatin (CDDP) loaded nanoparticles were applied for the in vitro and in vivo evaluation. The aim of this research was to develop FA modified SS bonds based prodrug of CDDP (namely FA-ss-CDDP) and Tf modified cystamine-oleic acid (Tf-ss-OA). Further, FA-ss-CDDP and Tf-ss-OA were used to prepare NPs, which could target the lung tumor cells through receptor-mediated pathways to increase the efficiency of CDDP. FA and Tf modified CDDP loaded NPs (FA/Tf-CDDP-NPs) were constructed. The physiochemical properties, in vitro drug release profiles, in vitro cytotoxicity, and in vivo biodistribution were investigated. The antitumor effect of self-assembed NPs was evaluated both in vitro and in vivo. FA/Tf-CDDP-NPs exhibited remarkably enhanced accumulation in tumor tissue and better tumor inhibition effect in vitro and in vivo. FA/Tf-CDDP-NPs displayed almost complete suppression of tumor growth with no obviously body weight change of the treated mice. The newly constructed NPs could successfully load drugs and showed better efficiency than free drug formula; and FA/TF could function as excellent targeting ligands to improve the cell targeting ability of the NPs. The resulting FA/Tf-CDDP-NPs offered a promising tumor therapy strategy for the treatment of lung cancer.
Collapse
Affiliation(s)
- Sheng Tan
- Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, 221000, PR China.
| | - Guoxiang Wang
- Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, 221000, PR China
| |
Collapse
|
83
|
Song Y, Cai H, Yin T, Huo M, Ma P, Zhou J, Lai W. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment. Int J Nanomedicine 2018; 13:1585-1600. [PMID: 29588586 PMCID: PMC5858821 DOI: 10.2147/ijn.s155383] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Background Lung cancer is the primary cause of cancer-related death worldwide. A redox-sensitive nanocarrier system was developed for tumor-targeted drug delivery and sufficient drug release of the chemotherapeutic agent paclitaxel (PTX) for improved lung cancer treatment. Methods The redox-sensitive nanocarrier system constructed from a hyaluronic acid-disulfide-vitamin E succinate (HA-SS-VES, HSV) conjugate was synthesized and PTX was loaded in the delivery system. The physicochemical properties of the HSV nanoparticles were characterized. The redox-sensitivity, tumor-targeting and intracellular drug release capability of the HSV nanoparticles were evaluated. Furthermore, in vitro and in vivo antitumor activity of the PTX-loaded HSV nanoparticles was investigated in a CD44 over-expressed A549 tumor model. Results This HSV conjugate was successfully synthesized and self-assembled to form nanoparticles in aqueous condition with a low critical micelle concentration of 36.3 μg mL−1. Free PTX was successfully entrapped into the HSV nanoparticles with a high drug loading of 33.5% (w/w) and an entrapment efficiency of 90.6%. Moreover, the redox-sensitivity of the HSV nanoparticles was confirmed by particle size change of the nanoparticles along with in vitro release profiles in different reducing environment. In addition, the HA-receptor mediated endocytosis and the potency of redox-sensitivity for intracellular drug delivery were further verified by flow cytometry and confocal laser scanning microscopic analysis. The antitumor activity results showed that compared to redox-insensitive nanoparticles and Taxol®, PTX-loaded redox-sensitive nanoparticles exhibited much greater in vitro cytotoxicity and apoptosis-inducing ability against CD44 over-expressed A549 tumor cells. In vivo, the PTX-loaded HSV nanoparticles possessed much higher antitumor efficacy in an A549 mouse xenograft model and demonstrated improved safety profile. In summary, our PTX-loaded redox-sensitive HSV nanoparticles demonstrated enhanced antitumor efficacy and improved safety of PTX. Conclusion The results of our study indicated the redox-sensitive HSV nanoparticle was a promising nanocarrier for lung cancer therapy.
Collapse
Affiliation(s)
- Yu Song
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.,College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| | - Han Cai
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China
| | - Tingjie Yin
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China
| | - Meirong Huo
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China
| | - Ping Ma
- Formulation Development, Tolmar Inc, Fort Collins, CO, USA
| | - Jianping Zhou
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China
| | - Wenfang Lai
- College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, People's Republic of China
| |
Collapse
|
84
|
Das S, Angsantikul P, Le C, Bao D, Miyamoto Y, Gao W, Zhang L, Eckmann L. Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera. PLoS Negl Trop Dis 2018; 12:e0006266. [PMID: 29470490 PMCID: PMC5839590 DOI: 10.1371/journal.pntd.0006266] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Revised: 03/06/2018] [Accepted: 01/24/2018] [Indexed: 01/16/2023] Open
Abstract
Diarrheal diseases are a major cause of morbidity and mortality worldwide. In many cases, antibiotic therapy is either ineffective or not recommended due to concerns about emergence of resistance. The pathogenesis of several of the most prevalent infections, including cholera and enteroxigenic Escherichia coli, is dominated by enterotoxins produced by lumen-dwelling pathogens before clearance by intestinal defenses. Toxins gain access to the host through critical host receptors, making these receptors attractive targets for alternative antimicrobial strategies that do not rely on conventional antibiotics. Here, we developed a new nanotechnology strategy as a countermeasure against cholera, one of the most important and prevalent toxin-mediated enteric infections. The key host receptor for cholera toxin, monosialotetrahexosylganglioside (GM1), was coated onto the surface of polymeric nanoparticles. The resulting GM1-polymer hybrid nanoparticles were shown to function as toxin decoys by selectively and stably binding cholera toxin, and neutralizing its actions on epithelial cells in vitro and in vivo. Furthermore, the GM1-coated nanoparticle decoys attenuated epithelial 3’,5’-cyclic adenosine monophosphate production and fluid responses to infection with live Vibrio cholera in cell culture and a murine infection model. Together, these studies illustrate that the new nanotechnology-based platform can be employed as a non-traditional antimicrobial strategy for the management of enteric infections with enterotoxin-producing pathogens. Diarrheal diseases are a major cause of suffering and death in the world, particularly in tropical regions with limited health care resources. Many of the most important diarrhea-causing microbes produce toxins that activate fluid secretion in the gut. A prototype pathogen in this category is the cause of cholera, Vibrio cholerae, which is characterized by profuse diarrhea and severe electrolyte disturbances due to the release of cholera toxin. Although treatment with fluids by mouth or injection can save patients from death, they still experience the devastating symptoms of the disease. In the present study, we have developed a new intervention strategy with engineered nanoparticles, particulates than are smaller than one millionth of a meter, which can neutralize cholera toxin in the gut before it can cause the characteristic disease manifestations. This strategy represents a novel interventional approach whose mechanism of action is different from currently existing therapies, thus significantly broadening the medical armamentarium against cholera and perhaps other gut infections that cause diseases dominated by toxin production.
Collapse
Affiliation(s)
- Soumita Das
- Department of Pathology, University of California, San Diego, La Jolla, California, United States of America
| | - Pavimol Angsantikul
- Department of Nanoengineering, University of California, San Diego, La Jolla, California, United States of America
| | - Christine Le
- Department of Medicine, University of California, San Diego, La Jolla, California, United States of America
| | - Denny Bao
- Department of Pathology, University of California, San Diego, La Jolla, California, United States of America
| | - Yukiko Miyamoto
- Department of Medicine, University of California, San Diego, La Jolla, California, United States of America
| | - Weiwei Gao
- Department of Nanoengineering, University of California, San Diego, La Jolla, California, United States of America
| | - Liangfang Zhang
- Department of Nanoengineering, University of California, San Diego, La Jolla, California, United States of America
- * E-mail: (LE); (LZ)
| | - Lars Eckmann
- Department of Medicine, University of California, San Diego, La Jolla, California, United States of America
- * E-mail: (LE); (LZ)
| |
Collapse
|
85
|
Interaction of antitumoral drug erlotinib with biodegradable triblock copolymers: a molecular modeling study. CHEMICAL PAPERS 2018. [DOI: 10.1007/s11696-018-0413-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
86
|
Kevadiya BD, Woldstad C, Ottemann BM, Dash P, Sajja BR, Lamberty B, Morsey B, Kocher T, Dutta R, Bade AN, Liu Y, Callen SE, Fox HS, Byrareddy SN, McMillan JM, Bronich TK, Edagwa BJ, Boska MD, Gendelman HE. Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 2018; 8:256-276. [PMID: 29290806 PMCID: PMC5743473 DOI: 10.7150/thno.22764] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2017] [Accepted: 10/06/2017] [Indexed: 01/23/2023] Open
Abstract
RATIONALE Long-acting slow effective release antiretroviral therapy (LASER ART) was developed to improve patient regimen adherence, prevent new infections, and facilitate drug delivery to human immunodeficiency virus cell and tissue reservoirs. In an effort to facilitate LASER ART development, "multimodal imaging theranostic nanoprobes" were created. These allow combined bioimaging, drug pharmacokinetics and tissue biodistribution tests in animal models. METHODS Europium (Eu3+)- doped cobalt ferrite (CF) dolutegravir (DTG)- loaded (EuCF-DTG) nanoparticles were synthesized then fully characterized based on their size, shape and stability. These were then used as platforms for nanoformulated drug biodistribution. RESULTS Folic acid (FA) decoration of EuCF-DTG (FA-EuCF-DTG) nanoparticles facilitated macrophage targeting and sped drug entry across cell barriers. Macrophage uptake was higher for FA-EuCF-DTG than EuCF-DTG nanoparticles with relaxivities of r2 = 546 mM-1s-1 and r2 = 564 mM-1s-1 in saline, and r2 = 850 mM-1s-1 and r2 = 876 mM-1s-1 in cells, respectively. The values were ten or more times higher than what was observed for ultrasmall superparamagnetic iron oxide particles (r2 = 31.15 mM-1s-1 in saline) using identical iron concentrations. Drug particles were detected in macrophage Rab compartments by dual fluorescence labeling. Replicate particles elicited sustained antiretroviral responses. After parenteral injection of FA-EuCF-DTG and EuCF-DTG into rats and rhesus macaques, drug, iron and cobalt levels, measured by LC-MS/MS, magnetic resonance imaging, and ICP-MS were coordinate. CONCLUSION We posit that these theranostic nanoprobes can assess LASER ART drug delivery and be used as part of a precision nanomedicine therapeutic strategy.
Collapse
Affiliation(s)
- Bhavesh D. Kevadiya
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Brendan M. Ottemann
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Prasanta Dash
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | | | - Benjamin Lamberty
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Brenda Morsey
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Ted Kocher
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Rinku Dutta
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Aditya N. Bade
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Yutong Liu
- Department of Radiology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Shannon E. Callen
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Howard S. Fox
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Siddappa N. Byrareddy
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - JoEllyn M. McMillan
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Tatiana K. Bronich
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| | - Benson J. Edagwa
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
| | - Michael D. Boska
- Department of Radiology, University of Nebraska Medical Center, Omaha, NE, USA
| | - Howard E. Gendelman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA
| |
Collapse
|
87
|
Dora CP, Kushwah V, Katiyar SS, Kumar P, Pillay V, Suresh S, Jain S. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. Int J Pharm 2017; 534:1-13. [PMID: 28970115 DOI: 10.1016/j.ijpharm.2017.09.071] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2017] [Revised: 08/25/2017] [Accepted: 09/29/2017] [Indexed: 12/18/2022]
Abstract
The current study was aimed to prepare a molecular complex of erlotinib (ERL) with phospholipid (PC) for enhancement of solubility and thus bioavailability, therapeutic efficacy and reducing the toxicity of erlotinib. Phospholipid complex of drug was prepared by solvent evaporation method and characterized by differential scanning calorimetry (DSC), Fourier transform infra-red spectroscopy (FT-IR), proton and phosphorus nuclear magnetic resonance spectroscopy (1H NMR and 31P NMR), powder X-ray diffraction (P-XRD), scanning electron microscopy (SEM) and transmission electron microscopy (TEM), which all explained the interactions of two components, validating the complexation phenomenon. In silico study also supported the phase change and molecular interactions for the establishment of ERL-PC. Spherical shaped nanostructures with 183.37±28.61nm size, -19.52±6.94mV potential and 28.59±2.66% loading efficiency were formed following dispersion of ERL-PC in aqueous media. In vitro release study revealed the higher release of ERL-PC due to amorphization and solubilization of drug. Caco-2 cell uptake resulted in ∼2 fold higher uptake of ERL-PC than free drug. In vitro cell culture studies were performed using human pancreatic adenocarcinoma cell lines, which demonstrated the higher cytotoxicity and apoptosis in case of ERL-PC. In vivo pharmacokinetics also supported the in vitro observations and showed ∼1.7 fold higher bioavailability with ERL-PC than ERL. Finally, in vivo efficacy and toxicity studies explained the superiority of ERL-PC over the free drug. Based on the results, phospholipid complex appears to be a promising tool to enhance bioavailability, efficacy, cytotoxicity and safety of erlotinib.
Collapse
Affiliation(s)
- Chander Parkash Dora
- Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab, 160062, India
| | - Varun Kushwah
- Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab, 160062, India
| | - Sameer S Katiyar
- Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab, 160062, India
| | - Pradeep Kumar
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Parktown, 2193, South Africa
| | - Viness Pillay
- Wits Advanced Drug Delivery Platform Research Unit, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Parktown, 2193, South Africa
| | - Sarasija Suresh
- Institute for Drug Delivery and Biomedical Research (IDBR), Bangalore, Karnataka, 560068, India; RGV Research & Innovations Pvt. Ltd (RGVRI), Bangalore, Karnataka, 560010, India
| | - Sanyog Jain
- Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab, 160062, India.
| |
Collapse
|
88
|
Date T, Nimbalkar V, Kamat J, Mittal A, Mahato RI, Chitkara D. Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. J Control Release 2017; 271:60-73. [PMID: 29273320 DOI: 10.1016/j.jconrel.2017.12.016] [Citation(s) in RCA: 99] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2017] [Revised: 12/15/2017] [Accepted: 12/17/2017] [Indexed: 01/11/2023]
Abstract
Cancer remained a major cause of death providing diversified challenges in terms of treatment including non-specific toxicity, chemoresistance and relapse. Nanotechnology- based delivery systems grabbed tremendous attention for delivering cancer therapeutics as they provide benefits including controlled drug release, improved biological half-life, reduced toxicity and targeted delivery. Majority of the nanocarriers consists of either a polymer or a lipid component along with other excipients to stabilize the colloidal system. Lipid-based systems provide advantages like better entrapment efficiency, scalability and low- cost raw materials, however, suffer from limitations including instability, a burst release of the drug, and limited surface functionalization. On the other hand, polymeric systems provide an excellent diversity of chemical modifications, stability, controlled release, however limited drug loading capacities and scale up limit their use. Hybrid nanocarriers consisting of lipid and polymer were able to overcome some of these disadvantages while retaining the advantages of both the systems. Designing a stable lipid-polymer hybrid system requires a thorough understanding of the material properties and their behavior in in vitro and in vivo environments. This review highlights the current status and future prospects of lipid-polymer hybrid systems with a particular focus on cancer nanotherapeutics.
Collapse
Affiliation(s)
- Tushar Date
- Department of Pharmacy, Birla Institute of Technology and Science-Pilani (BITS), Pilani Campus, Vidya Vihar, Pilani 333031, Rajasthan, India
| | - Vaishnavi Nimbalkar
- Department of Pharmacy, Birla Institute of Technology and Science-Pilani (BITS), Pilani Campus, Vidya Vihar, Pilani 333031, Rajasthan, India
| | - Jyostna Kamat
- Department of Pharmacy, Birla Institute of Technology and Science-Pilani (BITS), Pilani Campus, Vidya Vihar, Pilani 333031, Rajasthan, India
| | - Anupama Mittal
- Department of Pharmacy, Birla Institute of Technology and Science-Pilani (BITS), Pilani Campus, Vidya Vihar, Pilani 333031, Rajasthan, India
| | - Ram I Mahato
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 986125 Nebraska Medical Center, Omaha, NE 68198-6125, United States
| | - Deepak Chitkara
- Department of Pharmacy, Birla Institute of Technology and Science-Pilani (BITS), Pilani Campus, Vidya Vihar, Pilani 333031, Rajasthan, India.
| |
Collapse
|
89
|
Tan S, Wang G. Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo. DRUG DESIGN DEVELOPMENT AND THERAPY 2017; 11:3519-3529. [PMID: 29263650 PMCID: PMC5726363 DOI: 10.2147/dddt.s151422] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer (NSCLC). To overcome drug resistance and severe toxicities in the clinical application, redox-responsive and pH-sensitive nanoparticle drug delivery systems were designed for the encapsulation of ETB. Methods Poly(acrylic acid)-cystamine-oleic acid (PAA-ss-OA) was synthesized. PAA-ss-OA-modified ETB-loaded lipid nanoparticles (PAA-ETB-NPs) were prepared using the emulsification and solvent evaporation method. The tumor inhibition efficacy of PAA-ETB-NPs was compared with that of ETB-loaded lipid nanoparticles (ETB-NPs) and free ETB anticancer drugs in tumor-bearing mice. Results PAA-ETB-NPs had a size of 170 nm, with a zeta potential of −32 mV. The encapsulation efficiency and drug loading capacity of PAA-ETB-NPs were over 85% and 2.6%, respectively. In vitro cytotoxicity of ETB-NPs were higher than that of ETB solution. The cytotoxicity of PAA-ETB-NPs was the highest. The in vivo tumor growth inhibition by PAA-ETB-NP treatment was significantly higher than that by ETB-NPs and ETB solution. No obvious weight loss was observed in any of the treatment groups, indicating that all the treatments were well tolerated. Conclusion PAA-ETB-NPs could enhance the stability and anti-cancer ability of ETB to treat lung cancer and are a promising drug delivery system for lung cancer treatment.
Collapse
Affiliation(s)
- Sheng Tan
- Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China
| | - Guoxiang Wang
- Department of Thoracic Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China
| |
Collapse
|
90
|
Dabbagh A, Abu Kasim NH, Yeong CH, Wong TW, Abdul Rahman N. Critical Parameters for Particle-Based Pulmonary Delivery of Chemotherapeutics. J Aerosol Med Pulm Drug Deliv 2017; 31:139-154. [PMID: 29022837 DOI: 10.1089/jamp.2017.1382] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Targeted delivery of chemotherapeutics through the respiratory system is a potential approach to improve drug accumulation in the lung tumor, while decreasing their negative side effects. However, elimination by the pulmonary clearance mechanisms, including the mucociliary transport system, and ingestion by the alveolar macrophages, rapid absorption into the blood, enzymatic degradation, and low control over the deposition rate and location remain the main complications for achieving an effective pulmonary drug delivery. Therefore, particle-based delivery systems have emerged to minimize pulmonary clearance mechanisms, enhance drug therapeutic efficacy, and control the release behavior. A successful implementation of a particle-based delivery system requires understanding the influential parameters in terms of drug carrier, inhalation technology, and health status of the patient's respiratory system. This review aims at investigating the parameters that significantly drive the clinical outcomes of various particle-based pulmonary delivery systems. This should aid clinicians in appropriate selection of a delivery system according to their clinical setting. It will also guide researchers in addressing the remaining challenges that need to be overcome to enhance the efficiency of current pulmonary delivery systems for aerosols.
Collapse
Affiliation(s)
- Ali Dabbagh
- 1 Wellness Research Cluster, Institute of Research Management and Services, University of Malaya , Kuala Lumpur, Malaysia
| | - Noor Hayaty Abu Kasim
- 1 Wellness Research Cluster, Institute of Research Management and Services, University of Malaya , Kuala Lumpur, Malaysia
| | - Chai Hong Yeong
- 2 Department of Biomedical Imaging, Faculty of Medicine, University of Malaya , Kuala Lumpur, Malaysia
| | - Tin Wui Wong
- 3 Department of Pharmaceutics and Pharmaceutical Biotechnology, Faculty of Pharmacy, Universiti Teknologi MARA , Puncak Alam, Malaysia
| | - Noorsaadah Abdul Rahman
- 4 Department of Chemistry, Faculty of Science, University of Malaya , Kuala Lumpur, Malaysia .,5 Drug Design and Development Research Group (DDDRG), University of Malaya , Kuala Lumpur, Malaysia
| |
Collapse
|
91
|
Noorani M, Azarpira N, Karimian K, Heli H. Erlotinib-loaded albumin nanoparticles: A novel injectable form of erlotinib and its in vivo efficacy against pancreatic adenocarcinoma ASPC-1 and PANC-1 cell lines. Int J Pharm 2017; 531:299-305. [DOI: 10.1016/j.ijpharm.2017.08.102] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2017] [Revised: 08/17/2017] [Accepted: 08/21/2017] [Indexed: 02/07/2023]
|
92
|
Tahir N, Madni A, Balasubramanian V, Rehman M, Correia A, Kashif PM, Mäkilä E, Salonen J, Santos HA. Development and optimization of methotrexate-loaded lipid-polymer hybrid nanoparticles for controlled drug delivery applications. Int J Pharm 2017; 533:156-168. [PMID: 28963013 DOI: 10.1016/j.ijpharm.2017.09.061] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 09/20/2017] [Accepted: 09/21/2017] [Indexed: 12/22/2022]
Abstract
Lipid-polymer hybrid nanoparticles (LPHNPs) are emerging platforms for drug delivery applications. In the present study, methotrexate loaded LPHNPs consisted of PLGA and Lipoid S100 were fabricated by employing a single-step modified nanoprecipitation method combined with self-assembly. A three factor, three level Box Behnken design using Design-Expert® software was employed to access the influence of three independent variables on the particle size, drug entrapment and percent drug release. The optimized formulation was selected through numeric optimization approach. The results were supported with the ANOVA analysis, regression equations and response surface plots. Transmission electron microscope images indicated the nanosized and spherical shape of the LPHNPs with fair size distribution. The nanoparticles ranged from 176 to 308nm, which increased with increased polymer concentration. The increase in polymer and lipid concentration also increased the drug entrapment efficiency. The in vitro drug release was in range 70.34-91.95% and the release mechanism follow the Higuchi model (R2=0.9888) and Fickian diffusion (n<0.5). The in vitro cytotoxicity assay and confocal microscopy of the optimized formulation demonstrate the good safety and better internalization of the LPHNPs. The cell antiproliferation showed the spatial and controlled action of the nanoformulation as compared to the plain drug solution. The results suggest that LPHNPs can be a promising delivery system envisioned to safe, stable and potentially controlled delivery of methotrexate to the cancer cells to achieve better therapeutic outcomes.
Collapse
Affiliation(s)
- Nayab Tahir
- Department of Pharmacy, The Islamia University of Bahawalpur, 63100 Bahawalpur, Pakistan; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland
| | - Asadullah Madni
- Department of Pharmacy, The Islamia University of Bahawalpur, 63100 Bahawalpur, Pakistan.
| | - Vimalkumar Balasubramanian
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland
| | - Mubashar Rehman
- Department of Pharmacy, The Islamia University of Bahawalpur, 63100 Bahawalpur, Pakistan
| | - Alexandra Correia
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland
| | - Prince Muhammad Kashif
- Department of Pharmacy, The Islamia University of Bahawalpur, 63100 Bahawalpur, Pakistan
| | - Ermei Mäkilä
- Laboratory of Industrial Physics, Department of Physics, University of Turku, FI-20014 Turku, Finland
| | - Jarno Salonen
- Laboratory of Industrial Physics, Department of Physics, University of Turku, FI-20014 Turku, Finland
| | - Hélder A Santos
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014 Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, FI-00014 Helsinki, Finland.
| |
Collapse
|
93
|
Teixeira MC, Carbone C, Souto EB. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery. Prog Lipid Res 2017; 68:1-11. [PMID: 28778472 DOI: 10.1016/j.plipres.2017.07.001] [Citation(s) in RCA: 103] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2017] [Revised: 07/28/2017] [Accepted: 07/30/2017] [Indexed: 01/03/2023]
Abstract
Solid lipid nanoparticle (SLN), nanostructured lipid carriers (NLC) and hybrid nanoparticles, have gained increasing interest as drug delivery systems because of their potential to load and release drugs from the Biopharmaceutical classification system (BCS) of class II (low solubility and high permeability) and of class IV (low solubility and low permeability). Lipid properties (e.g. high solubilizing potential, biocompatibility, biotolerability, biodegradability and distinct route of absorption) contribute for the improvement of the bioavailability of these drugs for a set of administration routes. Their interest continues to grow, as translated by the number of patents being field worldwide. This paper discusses the recent advances on the use of SLN, NLC and lipid-polymer hybrid nanoparticles for the loading of lipophilic, poorly water-soluble and poorly permeable drugs, being developed for oral, topical, parenteral and ocular administration, also discussing the industrial applications of these systems. A review of the patents filled between 2014 and 2017, concerning the original inventions of lipid nanocarriers, is also provided.
Collapse
Affiliation(s)
- M C Teixeira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
| | - C Carbone
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Laboratory of Drug Delivery Technology, Dept. of Drug Sciences, University of Catania, Catania, Italy
| | - E B Souto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
| |
Collapse
|
94
|
Sengel-Turk CT, Hascicek C. Design of lipid-polymer hybrid nanoparticles for therapy of BPH: Part I. Formulation optimization using a design of experiment approach. J Drug Deliv Sci Technol 2017. [DOI: 10.1016/j.jddst.2017.02.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
95
|
Yang KM, Shin IC, Park JW, Kim KS, Kim DK, Park K, Kim K. Nanoparticulation improves bioavailability of Erlotinib. Drug Dev Ind Pharm 2017; 43:1557-1565. [PMID: 28554216 DOI: 10.1080/03639045.2017.1326931] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
OBJECTIVES Nanoparticulation using fat and supercritical fluid (NUFSTM) is a drug delivery platform technology enabling efficient and effective formulation of poorly soluble drugs. We performed experiments to examine whether NUFS™ could improve poor bioavailability and reduce fed-fasted bioavailability variances of erlotinib (Ert). METHODS NUFS-Ert was prepared using NUFS™ technology; its physical properties were characterized, and drug release was measured. Furthermore, in vitro and in vivo efficacy tests and pharmacokinetic analysis were performed. RESULTS NUFS-Ert nanoparticles had an average size of 250 nm and were stable for 2 months at 40 °C, 4 °C, and room temperature. The dissolution rate of NUFS-Ert increased in bio-relevant dissolution media. NUFS-Ert was more potent in inhibiting EGF signaling and in suppressing the proliferation of A549, a human non-small cell lung cancer cell line. Furthermore, A549 xenografts in BALB/c nude mice treated with NUFS-Ert regressed more efficiently than those in the mice treated with vehicle or Tarceva®. In addition, experimental lung metastasis was more efficiently inhibited by NUFS-Ert than by Tarceva®. The relative bioavailability of NUFS-Ert compared with that of Tarceva® was 550% and the ratio of the area under the concentration-time curve (AUC) of fed state to the AUC of fasted state was 1.8 for NUFS-Ert and 5.8 for Tarceva®. CONCLUSIONS NUFS-Ert could improve poor bioavailability and reduce fed-fasted bioavailability variances of Ert. NUFS-Ert was more efficacious than Tarceva®.
Collapse
Affiliation(s)
- Kyung Mi Yang
- a Department of Biochemistry and Molecular Biology , Yonsei University College of Medicine , Seoul , Korea
| | - In Chul Shin
- c Department of Health, Social, Clinical Pharmacy , College of Pharmacy, Chung-Ang University , Seoul , Korea
| | | | | | - Dae Kyong Kim
- c Department of Health, Social, Clinical Pharmacy , College of Pharmacy, Chung-Ang University , Seoul , Korea
| | - Kyungmoon Park
- e Department of Biological and Chemical Engineering , Hongik University , Sejong , Korea
| | - Kunhong Kim
- a Department of Biochemistry and Molecular Biology , Yonsei University College of Medicine , Seoul , Korea.,b Integrated Genomic Research Center for Metabolic Regulation , Seoul , Korea
| |
Collapse
|
96
|
Li Q, Cai T, Huang Y, Xia X, Cole SPC, Cai Y. A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs. NANOMATERIALS 2017; 7:nano7060122. [PMID: 28554993 PMCID: PMC5485769 DOI: 10.3390/nano7060122] [Citation(s) in RCA: 119] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 05/09/2017] [Accepted: 05/16/2017] [Indexed: 01/17/2023]
Abstract
Nanostructured lipid carriers (NLCs) are modified solid lipid nanoparticles (SLNs) that retain the characteristics of the SLN, improve drug stability and loading capacity, and prevent drug leakage. Polymer nanoparticles (PNPs) are an important component of drug delivery. These nanoparticles can effectively direct drug delivery to specific targets and improve drug stability and controlled drug release. Lipid–polymer nanoparticles (PLNs), a new type of carrier that combines liposomes and polymers, have been employed in recent years. These nanoparticles possess the complementary advantages of PNPs and liposomes. A PLN is composed of a core–shell structure; the polymer core provides a stable structure, and the phospholipid shell offers good biocompatibility. As such, the two components increase the drug encapsulation efficiency rate, facilitate surface modification, and prevent leakage of water-soluble drugs. Hence, we have reviewed the current state of development for the NLCs’, PNPs’, and PLNs’ structures, preparation, and applications over the past five years, to provide the basis for further study on a controlled release drug delivery system.
Collapse
Affiliation(s)
- Qianwen Li
- College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Tiange Cai
- College of Life Sciences, Liaoning University, Shenyang 110036, China.
| | - Yinghong Huang
- GuangzhouGuoyu Pharmaceutical Technology Co., Ltd., Guangzhou 510632, China.
| | - Xi Xia
- College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Susan P C Cole
- Division of Cancer Biology and Genetics, Queen's University Cancer Research Institute, Kingston, ON K7L 3N6, Canada.
| | - Yu Cai
- College of Pharmacy, Jinan University, Guangzhou 510632, China.
- Cancer Research Institute of Jinan University, Guangzhou 510632, China.
| |
Collapse
|
97
|
Zhu B, Yu L, Yue Q. Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy. Biomed Pharmacother 2017; 91:287-294. [PMID: 28463792 DOI: 10.1016/j.biopha.2017.02.112] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Revised: 02/09/2017] [Accepted: 02/15/2017] [Indexed: 12/18/2022] Open
Abstract
PURPOSE Chemotherapy is the current standard treatment for Non-Hodgkin's lymphoma (NHL). Combination therapy is emerging as an important strategy for a better long-term prognosis with decreased side effects, maximized therapeutic effect. The aim of this study is to deliver vincristine (VCR) and quercetin (QU) with synergistic drug ratios through lipid-polymeric nanocarriers (LPNs) for the lymphoma combination chemotherapy METHODS: In this present study, we constructed VCR and QU dual-loaded LPNs (VCR/QU LPNs) and investigated their antitumor efficacy in vitro cell culture models and a tumor xenograft mouse model. RESULTS The formulated VCR/QU LPNs exhibited nano-size, negative zeta potential with sustained release profile in vitro. The dual drug loaded LPNs exhibited the best antitumor efficacy in vitro and in vivo. CONCLUSION It could be concluded that VCR/QU LPNs can combine the efficiency of these two drugs, bring about synergistic effect. Co-encapsulation of VCR and QN in the same LPNs has potential as a novel therapeutic approach to overcome chemo-resistant lymphoma.
Collapse
Affiliation(s)
- Baomin Zhu
- Department of Blood Transfusion, Linyi People's Hospital, Linyi, Shandong, PR China
| | - Lianling Yu
- Department of Blood Transfusion, Linyi People's Hospital, Linyi, Shandong, PR China
| | - QingCai Yue
- Department of Endocrinology, Linyi People's Hospital, Linyi, Shandong, PR China.
| |
Collapse
|
98
|
Sheikhpour M, Barani L, Kasaeian A. Biomimetics in drug delivery systems: A critical review. J Control Release 2017; 253:97-109. [PMID: 28322976 DOI: 10.1016/j.jconrel.2017.03.026] [Citation(s) in RCA: 98] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 03/14/2017] [Accepted: 03/16/2017] [Indexed: 11/19/2022]
Abstract
Today, the advanced drug delivery systems have been focused on targeted drug delivery fields. The novel drug delivery is involved with the improvement of the capacity of drug loading in drug carriers, cellular uptake of drug carriers, and the sustained release of drugs within target cells. In this review, six groups of therapeutic drug carriers including biomimetic hydrogels, biomimetic micelles, biomimetic liposomes, biomimetic dendrimers, biomimetic polymeric carriers and biomimetic nanostructures, are studied. The subject takes advantage of the biomimetic methods of productions or the biomimetic techniques for the surface modifications, similar to what accrues in natural cells. Moreover, the effects of these biomimetic approaches for promoting the drug efficiency in targeted drug delivery are visible. The study demonstrates that the fabrication of biomimetic nanocomposite drug carriers could noticeably promote the efficiency of drugs in targeted drug delivery systems.
Collapse
Affiliation(s)
- Mojgan Sheikhpour
- Faculty of Biology, College of Science, University of Tehran, Tehran, Iran.
| | - Leila Barani
- Faculty of Chemical Engineering, University of Tehran, Tehran, Iran
| | - Alibakhsh Kasaeian
- Faculty of New Science & Technologies, University of Tehran, Tehran, Iran
| |
Collapse
|
99
|
Ma P, Li T, Xing H, Wang S, Sun Y, Sheng X, Wang K. Local anesthetic effects of bupivacaine loaded lipid-polymer hybrid nanoparticles: In vitro and in vivo evaluation. Biomed Pharmacother 2017; 89:689-695. [PMID: 28267672 DOI: 10.1016/j.biopha.2017.01.175] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 01/16/2017] [Accepted: 01/16/2017] [Indexed: 11/25/2022] Open
Abstract
PURPOSE There is a compelling need for prolonged local anesthetic that would be used for analgesia with a single administration. However, due to the low molecular weight of local anesthetics (LA) (lidocaine, bupivacaine, procaine, dibucaine, etc), they present fast systemic absorption. METHODS The aim of the present study was to develop and evaluate bupivacaine lipid-polymer hybrid nanoparticles (BVC LPNs), and compared with BVC loaded PLGA nanoparticles (BVC NPs). Their morphology, particle size, zeta potential and drug loading capacity were evaluated. In vitro release study, stability and cytotoxicity were studied. In vivo evaluation of anesthetic effects was performed on animal models. RESULTS A facile nanoprecipitation and self-assembly method was optimized to obtain BVC LPNs, composed of PLGA, lecithin and DSPE-PEG2000, of ∼175nm particle size. Compared to BVC NPs, BVC LPNs exhibited prolonged in vitro release in phosphate-buffered saline (pH=7.4). Further, BVC LPNs displayed enhanced in vitro stability in 10% FBS and lower cytotoxicity (the concentration of BVC ranging from 1.0μM to 20μM). In addition, BVC LPNs exhibited significantly prolonged analgesic duration. CONCLUSION These results demonstrate that the LPNs could function as promising drug delivery system for overcoming the drawbacks of poor stability and rapid drug leakage, and prolonging the anesthetic effect with slight toxicity.
Collapse
Affiliation(s)
- Pengju Ma
- Department of Anesthesiology, Anqiu People's Hospital, Anqiu 262100, Shandong Province, China
| | - Ting Li
- Delivery Room, People's Hospital of Anqiu, Anqiu 262100, Shandong Province, China
| | - Huaixin Xing
- Department of Anesthesiology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, Shandong Province, China.
| | - Suzhen Wang
- Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong Province, China
| | - Yingui Sun
- Department of Anesthesiology, Weifang Medical University, Weifang 261042, Shandong Province, China
| | - Xiugui Sheng
- Department of Gynecological Tumor, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong Province, China
| | - Kaiguo Wang
- Department of Anesthesiology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong Province, China
| |
Collapse
|
100
|
Madni A, Batool A, Noreen S, Maqbool I, Rehman F, Kashif PM, Tahir N, Raza A. Novel nanoparticulate systems for lung cancer therapy: an updated review. J Drug Target 2017; 25:499-512. [PMID: 28151021 DOI: 10.1080/1061186x.2017.1289540] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Lung cancer is the leading cause of cancer-related deaths in the world. Conventional therapy for lung cancer is associated with lack of specificity and access to the normal cells resulting in cytotoxicity, reduced cellular uptake, drug resistance and rapid drug clearance from the body. The emergence of nanotechnology has revolutionized the treatment of lung cancer. The focus of nanotechnology is to target tumor cells with improved bioavailability and reduced toxicity. In the recent years, nanoparticulate systems have extensively been exploited in order to overcome the obstacles in treatment of lung cancer. Nanoparticulate systems have shown much potential for lung cancer therapy by gaining selective access to the tumor cells due to surface modifiability and smaller size. In this review, various novel nanoparticles (NPs) based formulations have been discussed in the treatment of lung cancer. Nanotechnology is expected to grow fast in future, and it will provide new avenues for the improved treatment of lung cancer. This review article also highlights the characteristics, recent advances in the designing of NPs and therapeutic outcomes.
Collapse
Affiliation(s)
- Asadullah Madni
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Amna Batool
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Sobia Noreen
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Irsah Maqbool
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Faizza Rehman
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Prince Muhammad Kashif
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Nayab Tahir
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| | - Ahmad Raza
- a Department of Pharmacy, Faculty of Pharmacy & Alternative Medicine , The Islamia University of Bahawalpur , Bahawalpur , Pakistan
| |
Collapse
|